Applicant, as named in the Orange Book
Intra-Cellular
Johnson & Johnson · NYSE: JNJ
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Caplyta on 10 Dec 2040. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Caplyta NDA 209500 · 3 strengths lumateperone tosylate | 10 Dec 2040 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.